Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
In this Phase I study, the primary objective is to investigate the safety and tolerability of
SKI2670 after oral administration in healthy female subjects. And secondary objective is to
investigate the pharmacokinetics and pharmacodynamics of SKI2670 after oral administration in
healthy female subjects.